Tonix Pharmaceuticals Secures GPO Coverage for TONMYA Reaching 35 Million Commercial Lives

Sublingual cyclobenzaprine's commercial viability now hinges on payer access as much as formulation science: Tonix Pharmaceuticals has secured a coverage agreement with a leading group purchasing organization (GPO), effective May 1, 2026, extending TONMYA® (cyclobenzaprine HCl sublingual tablets) to approximately 35 million U.S. commercial lives, roughly 20% of the 177 million commercial lives nationally.

TONMYA received FDA approval on August 15, 2025, as the first new prescription treatment for fibromyalgia in adults in more than 15 years, and entered commercial distribution in November 2025. The sublingual tablet formulation is designed to bypass first-pass hepatic metabolism, enabling rapid transmucosal absorption while reducing systemic exposure to norcyclobenzaprine, the long half-life active metabolite associated with tolerability concerns in oral cyclobenzaprine. For manufacturing and QA teams, that pharmacokinetic profile reflects deliberate formulation choices that carry their own process validation and dissolution testing obligations under 21 CFR Part 211.

The GPO agreement applies standard utilization management criteria, meaning formulary access will be subject to prior authorization or step-therapy protocols depending on individual payer contracts. Tonix has separately confirmed Medicaid coverage in 38 states, covering approximately 55 million lives, 73% of the roughly 75 million Medicaid-eligible population, with Medicare and Medicaid discussions ongoing.

The fibromyalgia patient population exceeds 10 million U.S. adults, approximately 90% of whom are women. Published data cited by Tonix indicates that 85% of first-line treatments fail due to efficacy or tolerability issues, a gap that informed TONMYA's receptor-binding profile targeting 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic pathways. For regulatory affairs leads tracking the product's post-approval commitments, the multifunctional mechanism and sublingual route each carry distinct labeling and pharmacovigilance considerations as real-world utilization scales.

Tonix also operates the TONMYA Together Support Program, offering savings to eligible commercially insured patients through local and digital pharmacy channels, a structure that will affect dispensing volume forecasts relevant to commercial-scale batch planning and supply continuity.

The pace at which Tonix converts ongoing Medicare negotiations into formulary placements will serve as the next measurable indicator of whether TONMYA's commercial infrastructure can support the patient volumes its payer agreements are beginning to unlock.

Source: Tonix Pharmaceuticals via GlobeNewswire, May 6, 2026.